Use of protein C concentrate in critical conditions: Clinical experience in pediatric patients with sepsis;Il concentrato di proteina C negli stati critici: L'Esperienza clinica nei pazienti pediatrici settici

Minerva Anestesiologica

Volumn 70, Issue 5, 2004, Pages 357-363

  Pettenazzo, A ^a   Malusa, T ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Child; Protein C; Sepsis

Indexed keywords

DROTRECOGIN; PROTEIN C;

ARTICLE; BLEEDING; CHILD; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; ENTEROVIRUS; FEMALE; FULMINATING PURPURA; HUMAN; INTENSIVE CARE UNIT; MALE; MENINGOCOCCEMIA; MORBIDITY; PROTEIN C DEFICIENCY; PSEUDOMONAS AERUGINOSA; SEPSIS; SEPTIC SHOCK; SERRATIA MARCESCENS; THROMBOSIS;

CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; FEMALE; HUMANS; INFANT; MALE; PROTEIN C; SEPSIS;

EID: 3142686146     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1472-4.
2. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003;167:695-701.
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WN et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, The ACCP/SCCM Consensus Conference Committee. AmericanCollege of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
4. Derkx B, Wittes J, McCLoskey R, the European Pediatric Meningococcal Septic Shock Trial Study Group. Randomised, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin Infect Dis 1999;28:770-7.
5. Reinhart K, Wiegand-Lohnert C, Grimininger F, Kaul M, Withington S, Treacher D et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24: 733-42.
6. Heyderman RS. Severe sepsis and intravascular thrombosis. Arch Dis Child 1993;68:621-5.
7. Hazelzet JA, Risseeuw-Appel IM, Kornelisse RF, Hop WC, Dekker I, Joosten KF et al. Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost 1996;76:932-8.
8. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995;73:15-20.
9. Esmon CT. Protein C anticoagulant pathway an dits role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001;29:S48-52.
10. Hartman DL, Helterbrand JD, Bernard GR. Protein C (PC) level in sepsis: association with mortality. Am J Respir Crit Care Med 1997;155: A708.
11. Fisher CJ, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related disease. Crit Care Med 2000;28:S49-56.
12. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995;126:646-52.
13. Leclerc F, Hazelzet J, Jude B, Hofhuis W, Hue V, Martinot A, et al. Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med 1992;18:202-5.
14. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
15. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH et al. Effects of drotrecogin alfa (activated) on organ disfunction in the PROWESS trial. Crit Care Med 2003;31:834-40.
16. Barton PB, Kalil C, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 2004;113:7-17.
17. Petaja J, Manco-Johnson M. Protein C pathway in infants and children, Serum Thromb Hemost 2003;29:349-61.
18. Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meninococcus-induced purpura fulminans. Lancet 1997;350:1590-3.
19. Thompson APJ, Sills JA, Hart CA. Validation of the Glasgow meningococcal septicemia prognostic score: a 10 year retrospective survey. Crit Care Med 1991; 19:26-30.
20. Kuhule S, Male C, Mitchell M. Developmental hemostasis: Pro- and anticoagulant svstem during childhood. Sem Thromb Hemost 2003;29:329-37.
21. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of adjiuvant haemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000;96:3719-24.
22. Genoff MC, Hoffer MM, Achauer B, Formosa P. Extremity amputations in meningococcemia-induced purpura fulminans. Plast Reconstr Surg 1992; 89:878-81.
23. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345: 408-16.
24. de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose finding study. Crit Care Med 2003;31:1839-47.
25. Rintala E, Kauppila M, Seppala OP, Voipio-Pulkki LM, Pettila V, Rasi V, et al. Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 2000;28: 2373-8.
26. Kreuz W, Veldman A, Escuriola-Ettingshausen C, Schneider W, Beeg T. Protein-C concentrate for meningococcal purpura fulminans. Lancet 1998;351: 986-7.
27. Leclerc F, Cremer R, Leteurtre S, Martinot A, Fourier C. Protein C concentrate and recombinant tissue plasminogen activator in meningococcal septic shock. Crit Care Med 2000:28:1694-7.